This therapeutic concept uses CRISPR interference (CRISPRi) — a catalytically dead Cas9 (dCas9) fused to the KRAB transcriptional repressor domain — to achieve durable epigenetic silencing of the SNCA gene that encodes alpha-synuclein. Unlike gene knockout or ASO knockdown, CRISPRi deposits repressive H3K9me3 chromatin marks at the SNCA promoter, achieving long-lasting (months to years) transcriptional silencing without DNA cutting, insertional mutagenesis, or permanent genomic alteration. Reducing alpha-synuclein expression by 50-70% in vulnerable dopaminergic neurons could prevent protein aggregation and halt Parkinson's disease progression — a gene-dosage approach validated by the observation that SNCA gene duplications and triplications cause familial PD with severity proportional to copy number.[1][2]
Alpha-synuclein dosage is a validated disease driver: SNCA duplications cause autosomal dominant PD with ~40% penetrance, while triplications cause early-onset PD with dementia and 100% penetrance. Genome-wide association studies identify the SNCA locus as the strongest risk factor for sporadic PD, with risk alleles increasing expression by 10-20%.[3] This establishes that even modest reduction in alpha-synuclein levels should be protective.
CRISPRi advantages over competing approaches:
SNCA is the most genetically validated target in PD. GWAS, familial genetics, and animal models all converge on alpha-synuclein dosage as a causal driver. CRISPRi silencing in the substantia nigra could be administered at the prodromal stage (identified by alpha-synuclein seed amplification assay or DAT-SPECT) to prevent clinical PD.[5]
Cortical alpha-synuclein accumulation drives DLB. Broader CRISPRi distribution via intrathecal AAV could reduce cortical SNCA expression.
Oligodendroglial alpha-synuclein aggregation is the hallmark. AAV serotypes with oligodendrocyte tropism (AAVcy.1) could enable CRISPRi in the relevant cell type.
GBA1 mutations impair alpha-synuclein clearance. Reducing production via CRISPRi would decrease the burden on the compromised lysosomal pathway.[6]
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 9 | CRISPRi for neurodegeneration not yet in clinical trials; epigenetic silencing is a new therapeutic paradigm |
| Mechanistic Rationale | 9 | Gene dosage as PD driver is among the most validated hypotheses in neurodegeneration |
| Addresses Root Cause | 9 | Directly reduces the aggregation-prone protein at the transcriptional level |
| Delivery Feasibility | 5 | AAV-mediated CNS delivery is feasible but dCas9 size (4.2 kb) + sgRNA challenges single-AAV packaging |
| Safety Plausibility | 6 | Complete SNCA silencing impairs synaptic vesicle release; must titrate to partial knockdown |
| Combinability | 7 | Compatible with GCase activators, anti-inflammatory agents, and exercise interventions |
| Biomarker Availability | 8 | CSF alpha-synuclein SAA, DAT-SPECT, plasma NfL all available for monitoring[7] |
| De-risking Path | 7 | iPSC neurons, PFF models, and NHP intracisternal AAV delivery all established |
| Multi-disease Potential | 7 | PD, DLB, MSA, GBA-PD; platform generalizable to other gain-of-function neurodegeneration genes |
| Patient Impact | 9 | One-time injection could provide years of disease modification — potentially curative for genetic PD |
| Total | 76 |
Dose-response study:
Efficacy in PD models:
Biomarker development:
IND-enabling studies:
Clinical trial design:
| Partner Type | Organization | Value Proposition |
|---|---|---|
| Gene therapy | Spark Therapeutics, Neurocrine | RNAi/ASO pipeline gap — epigenetic silencing is longer-lasting |
| Pharma | AbbVie, Biogen | Expand Parkinson's pipeline with novel mechanism |
| Academic | Johns Hopkins, Columbia (K. Simuni, R. Alcalay) | Clinical trial sites, patient cohorts |
| Foundation | Michael J. Fox Foundation, Parkinson's Foundation | Funding, PPMI collaboration |
| Risk | Likelihood | Mitigation |
|---|---|---|
| AAV fails to transduce human dopaminergic neurons efficiently | Medium | Test multiple serotypes (AAV9, AAVrh10, AAV2.7m8); use enhanced promoters |
| Epigenetic silencing not durable in human neurons | Medium | Test KRAB vs. KRAB-MeCP2 fusions; verify H3K9me3 maintenance |
| Off-target H3K9me3 deposition | Low-Med | Genome-wide ChIP-seq; select sgRNAs with minimal collateral |
| Milestone | Timeline | Cost |
|---|---|---|
| AAV vector engineering for CNS tropism | Months 1-6 | $1.5M |
| dCas9-SNCA gRNA optimization | Months 3-9 | $1.0M |
| In vitro validation (iPSC neurons) | Months 6-12 | $0.8M |
| GLP toxicology package | Months 12-18 | $2.0M |
| IND-enabling studies | Months 15-18 | $1.2M |
| Phase 1 Total | $6.5M |
| Milestone | Timeline | Cost |
|---|---|---|
| Phase 1 safety (single dose) | Months 18-22 | $3.0M |
| Phase 1b multiple dose escalation | Months 22-28 | $4.0M |
| Phase 2 signal-finding | Months 28-36 | $8.0M |
| Phase 2 Total | $15.0M |
| Milestone | Timeline | Cost |
|---|---|---|
| Pivotal trial execution | Months 36-54 | $25.0M |
| CMC scale-up | Months 36-48 | $5.0M |
| Regulatory submissions | Months 54-60 | $3.0M |
| Phase 3 Total | $33.0M |
| Gate | Criteria | Go/No-Go |
|---|---|---|
| End of Phase 1 | Safety OK, target engagement >50% | Go |
| End of Phase 2 | SNCA reduction >30% in CSF | Go to Phase 3 |
Chartier-Harlin MC, Kachergus J, Roumier C, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet. 2004. ↩︎
Gilbert LA, Horlbeck MA, Adamson B, et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell. 2014. ↩︎ ↩︎
Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurology. 2019. ↩︎
Yeo NC, Chavez A, Lance-Byrne A, et al. An enhanced CRISPR repressor for targeted mammalian gene regulation. Nature Methods. 2018. ↩︎
Singleton AB, Farrer M, Johnson J, et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science. 2003. ↩︎
Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. New England Journal of Medicine. 2009. ↩︎
Siderowf A, Concha-Marambio L, Lafontant DE, et al. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using alpha-synuclein seed amplification. JAMA Neurology. 2023. ↩︎
Charlesworth CT, Deshpande PS, Dever DP, et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nature Medicine. 2019. ↩︎